Sean E. Collins

Sean E. Collins

Auto-generated profile, based on publicly available information

Sean E. Collins

VA Tennessee Valley Healthcare System

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in The Lancet HIV
Verified
Journal Article
Closed access
DWDavid A Wohl
David A Wohl
YYYazdan Yazdanpanah
Yazdan Yazdanpanah
ABAxel Baumgarten
Axel Baumgarten
ACAmanda Clarke
Amanda Clarke
MTMelanie A Thompson
Melanie A Thompson
HMHal Martin
Hal Martin

1 June 2020 in The Lancet HIV
Verified
Journal Article
Closed access
COChloe Orkin
Chloe Orkin
EDEdwin DeJesus
Edwin DeJesus
PSPaul E Sax
Paul E Sax
JAJose R Arribas
Jose R Arribas
SGSamir K Gupta
Samir K Gupta
HMHal Martin
Hal Martin

1 June 2019 in The Lancet HIV
Verified
Journal Article
Closed access
HSHans-Jürgen Stellbrink
Hans-Jürgen Stellbrink
JAJosé R Arribas
José R Arribas
JSJeffrey L Stephens
Jeffrey L Stephens
HAHelmut Albrecht
Helmut Albrecht
PSPaul E Sax
Paul E Sax
HMHal Martin
Hal Martin

15 July 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PSPaul E Sax
Paul E Sax
JRJürgen K Rockstroh
Jürgen K Rockstroh
ALAnne F Luetkemeyer
Anne F Luetkemeyer
YYYazdan Yazdanpanah
Yazdan Yazdanpanah
DWDouglas Ward
Douglas Ward
HMHal Martin
Hal Martin
Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1 (HIV-1). We evaluated whether people receiving dolutegravir (DTG) plus F/TAF or F/TDF (tenofovir disoproxil fumarate) with viral suppression can switch to B/F/TAF without compromising safety or efficacy, regardless of preexisting nucleoside reverse transcriptase inhibitor (NRTI) resistance. In this multicenter, randomized, double-blinded, active-controlled, noninferiority trial, we enrolled adults who were virologically suppressed for ≥6 months before screening (with documented/suspected NRTI resistance) or ≥3 months before screening (with no documented/suspected NRTI resistance) on DTG plus either F/TDF or F/TAF. We randomly assigned (1:1) participants to switch to B/F/TAF or DTG + F/TAF once daily for 48 weeks, each with matching placebo. The primary endpoint was proportion of participants with plasma HIV-1 RNA ≥50 copies/mL at week 48 (snapshot algorithm); the prespecified noninferiority margin was 4%. Five hundred sixty-seven adults were randomized; 565 were treated (284 B/F/TAF, 281 DTG + F/TAF). At week 48, B/F/TAF was noninferior to DTG + F/TAF, as 0.4% (1/284) vs 1.1% (3/281) had HIV-1 RNA ≥50 copies/mL (difference, −0.7% [95.001% confidence interval {CI}, −2.8% to 1.0%]). There were no significant differences in efficacy among participants with suspected or confirmed prior NRTI resistance (n = 138). No participant had treatment-emergent drug resistance. Median weight change from baseline at week 48 was +1.3 kg (B/F/TAF) vs +1.1 kg (DTG + F/TAF) (P = .46). Weight change differed by baseline NRTIs (+2.2 kg [F/TDF] and +0.6 kg [F/TAF], P < .001), with no differences between B/F/TAF and DTG + F/TAF. The single-tablet regimen B/F/TAF is a safe, effective option for people virologically suppressed on DTG plus either F/TDF or F/TAF, including in individuals with preexisting resistance to NRTIs. NCT03110380.

30 January 2024 in The Lancet HIV
Verified
Journal Article
Closed access
JEJoseph J Eron
Joseph J Eron
SLSusan J Little
Susan J Little
GCGordon Crofoot
Gordon Crofoot
PCPaul Cook
Paul Cook
PRPeter J Ruane
Peter J Ruane
MCMarina Caskey
Marina Caskey

12 August 2018 in HIV Medicine
Verified
Journal Article
Open access
PDF file
DHD Hagins
D Hagins
COC Orkin
C Orkin
EDEs Daar
Es Daar
AMA Mills
A Mills
CBC Brinson
C Brinson
MDM Das
M Das
Objectives: The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV‐1‐infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to RPV/FTC/TAF from either RPV/FTC/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF.Methods: We conducted two distinct randomized, double‐blind, active‐controlled, noninferiority trials in participants taking RPV/FTC/TDF (Study 1216) and EFV/FTC/TDF (Study 1160). Each study randomized virologically suppressed (HIV‐1 RNA < 50 copies/mL) adults (1:1) to switch to RPV/FTC/TAF or continue their current regimen for 96 weeks. We evaluated efficacy as the proportion with HIV‐1 RNA < 50 copies/mL using the Food and Drug Administration snapshot algorithm and prespecified bone and renal endpoints at week 96.Results: We randomized and treated 630 participants in Study 1216 (RPV/FTC/TAF, n = 316; RPV/FTC/TDF, n = 314) and 875 in Study 1160 (RPV/FTC/TAF, n = 438; EFV/FTC/TDF, n = 437). In both studies, the efficacy of switching to RPV/FTC/TAF was noninferior to that of continuing baseline therapy at week 96, with respective percentages of patients with HIV RNA < 50 copies/mL being 89.2% versus 88.5% in Study 1216 [difference 0.7%; 95% confidence interval (CI) −4.3 to +5.8%] and 85.2% versus 85.1% in Study 1160 (difference 0%; 95% CI −4.8 to +4.8%). No participant on RPV/FTC/TAF developed treatment‐emergent resistance versus two on EFV/FTC/TDF and one on RPV/FTC/TDF. Compared with continuing baseline therapy, significant improvements in bone mineral density and renal tubular markers were observed in the RPV/FTC/TAF groups (P < 0.001).Conclusions: Switching to RPV/FTC/TAF from RPV/FTC/TDF or EFV/FTC/TDF was safe and effective and improved bone mineral density and renal biomarkers up to 96 weeks with no cases of treatment‐emergent resistance.